SummaryGSK3532795 is a second-generation HIV-1 maturation inhibitor. In this phase 2a dose-ranging study, GSK3532795 demonstrated potent antiviral activity against both subtype B (monotherapy or atazanavir ± ritonavir) and subtype C (monotherapy), and was generally well tolerated. These data support continued development of GSK3532795.
Doravirine monotherapy demonstrated robust antiviral activity at both dose levels, without evidence of viral resistance, and was generally well tolerated. Doravirine pharmacokinetics in HIV-infected individuals were similar to those in uninfected individuals receiving similar doses in prior studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.